Getty Images You’ve probably been seeing headlines about yet another financial crash on the horizon. It’s true, the International Monetary Fund has released grim projections for the immediate future of world finance. Why? Well, it’s complicated. Basically, the forces which were put in place to fix the last recession may just have caused another bubble in another sector. The 2008 Recession The last bubble and subsequent recession were caused when Wall Street took on huge amounts of cheap debt. This debt, as it was repaid, was meant to pay off many times over. But the reality of the situation was much different. In many cases, the debt was put on the back of private individuals who couldn’t handle it, who shouldn’t have been offered a loan in the first place. They defaulted en masse and — among many other factors — it caused the bubble to pop. Debt is only worth something if it gets paid back, plus interest. In 2008 the whole house of cards collapsed. Massive firms like Lehman Brothers went under and a lot of money just disappeared. The ‘Brittle’ 2015 Global Market Things are different this time around and Wall Street isn’t on the hook. In an attempt to stabilize global markets following the last recession, borrowing has been made extremely cheap in developed economies like the United States. Economists thought this would shock the heartbeat of the pre-Crash economy back to life, but the U.S. was never able to wean borrowers off of ultra low rates. Investors of all sizes have been snapping up this cheap debt for several years now, causing many to worry that these are exactly the same conditions that caused the 2008 crash. There are other global factors which make this scenario different from that of 2008. This time, Wall Street isn’t the one holding all of this cheap debt. This time it’s spread all around the world, in companies, private investors and world governments. Many of the nations involved are so-called “developing” economies, which have been using cheap borrowing to fund expansion. What Does This Mean for You?
Top Long Term Companies For 2016: CytRx Corporation(CYTR)
CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics, specializing in oncology. Its drug development pipeline includes INNO-206, which is in Phase II clinical trials for the treatment of soft tissue sarcomas and is in Phase Ib/2 clinical trials for the treatment of solid tumors; and tamibarotene that is in Phase II clinical trials for the treatment of non-small-cell lung cancer and acute promyelocytic leukemia. The company also develops Bafetinib, which is in Phase II clinical trials for the treatment of B-cell chronic lymphocytic leukemia and advanced prostate cancer, as well as in pharmacokinetic clinical trial for brain cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
- [By Roberto Pedone]
Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.
If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.
Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top Long Term Companies For 2016: Rhino Resource Partners LP(RNO)
Rhino Resource Partners LP produces, processes, and sells coal of various steam and metallurgical grades in the United States. The company holds interests in various surface and underground coal mines located in Central Appalachia, Northern Appalachia, the Illinois Basin, and the Western Bituminous region. As of December 31, 2010, it operated 10 mines, including 5 underground and 5 surface mines located in Kentucky, Ohio, and West Virginia. The company markets its steam coal primarily to electric utility companies as fuel for their steam-powered generators; and metallurgical coal for steel and coke producers. It also engages in mining limestone from reserves located at its Sands Hill mining complex and sells it as aggregate to various construction companies and road builders. The company was founded in 2003 and is based in Lexington, Kentucky.
- [By Alexis Xydias]
Investors are regaining confidence, squeezing pessimists who say the economy remains sluggish outside of Germany and point to record-low trading volume as a lack of conviction in the Euro Stoxxs 61 percent rally of the past two years. Besides gains in stocks from Banco Bilbao Vizcaya Argentaria SA to Renault SA (RNO), yields on Spanish and Italian bonds have declined to a two-year low compared with German bunds and the euro has strengthened 4.6 percent to $1.35 in the past six months.
Top Prefered Companies To Invest In Right Now: Avanir Pharmaceuticals Inc(AVNR)
Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. The company primarily offers NUEDEXTA, a unique proprietary combination of dextromethorphan and low-dose quinidine for the treatment of pseudobulbar affect. Its product line also comprises AVP-923 in Phase II clinical trial for the treatment of central neuropathic pain in patients with multiple sclerosis; and in Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. In addition, the company provides Docosanol 10% cream, an over-the-counter product for cold sores treatment. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.
- [By Paul Ausick]
Stocks on the move: Galena Biopharma Inc. (NASDAQ: GALE) is down 15.4% at $1.93 after pricing a secondary offering of 17.5 million units at $2.00. Safeway Inc. (NYSE: SWY) is up 6.1% at $28.21, after an analysts upgrade which sent shares to a new 52-week high of $28.88 earlier. Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) is down 18.2% at $4.08.
Top Long Term Companies For 2016: Brown(n)
N Brown Group plc operates as an Internet and catalogue home shopping company in the United Kingdom. The company principally offers womenswear, menswear, footwear, household, and electrical products, as well as provides insurance services. It also operates in the Republic of Ireland, Germany, and the United States. The company was founded in 1859 and is based in Manchester, the United Kingdom.
- [By Alex Jordon]
He already owns a good chunk of NetSuite (N), whose revenue grew 35% last quarter, beating earnings estimates by $0.03 a share. Ellison’s been profiting from the cloud while dismissing its significance. With the Salesforce agreement his company is, too. (Fool)
Top Long Term Companies For 2016: Leucadia National Corporation(LUK)
Leucadia National Corporation, through its subsidiaries, engages in manufacturing, land based contract oil and gas drilling, gaming entertainment, real estate, medical product development, and winery operations in the United States and internationally. Its manufacturing operations include remanufacturing, manufacturing, and/or distribution dimension lumber, home center boards for retailers, pine decking, and other specialty wood products; and manufacturing and marketing lightweight plastic netting used in building and construction, erosion control, packaging, agricultural, carpet padding, filtration, and consumer products. The company?s land based contract oil and gas drilling operations include the provision of drilling services to independent oil and natural gas exploration and production companies in the Mid-Continent region of the United States, including Oklahoma, Texas, Arkansas, Louisiana, and Kansas. As of December 31, 2010, it had 38 drilling rigs. The company?s g aming entertainment operations consist of owning the Hard Rock Hotel & Casino Biloxi located in Biloxi, Mississippi, which consists of 325 rooms and suites, 1,268 slot machines, 52 table games, 6 live poker tables, 5 restaurants, and spa. Its real estate activities include investment in commercial properties, residential land development projects, and other unimproved land. The company?s medical product development operations comprise the development of MP4OX that has completed a phase II proof of concept clinical trial and is a solution of cell-free hemoglobin, administered intravenously to provide oxygen delivery to oxygen deprived tissues. In addition, Leucadia National Corporation engages in the production and sale of wines; and investment and evaluation of gasification projects to convert various types of low grade fossil fuels into energy products. The company was founded in 1854 and is based in New York, New York.
- [By Michael Hooper]
When compared with similar companies, Berkshire Hathaway carries a premium over Markel (NYSE: MKL ) , valued at 1.15 times book value and a 20 forward P/E ratio; and Leucadia National (NYSE: LUK ) , valued at 1.10 times book value and a 7.16 trailing P/E.